Literature DB >> 17934386

Treatment adherence and long-term outcomes.

John M Kane1.   

Abstract

The successful management of schizophrenia is an enormous public health issue. Although antipsychotic medications can be very helpful in reducing rates of relapse and rehospitalization, nonadherence to medication is a frequent cause of exacerbations in psychopathology, psychotic relapse, and rehospitalization. Relapses can have devastating consequences in a variety of clinical and functional domains. Nonadherence can result from a variety of factors that vary from patient to patient and vary over time in individual patients. A number of strategies have been developed to assess and facilitate adherence. The first critical step is clinician awareness of the scope of the problem and consideration of appropriate strategies to address it.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934386     DOI: 10.1017/s1092852900026304

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  30 in total

1.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

Review 2.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

3.  Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Rosario de Arce Cordón; Evelin Eding; Joao Marques-Teixeira; Vihra Milanova; Elmars Rancans; Andreas Schreiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-08-02       Impact factor: 5.270

4.  Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Authors:  Wolfgang Gaebel; Andreas Schreiner; Paul Bergmans; Rosario de Arce; Frédéric Rouillon; Joachim Cordes; Lars Eriksson; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

5.  Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).

Authors:  José María Pelayo-Terán; Virginia Gajardo Gajardo Galán; Víctor de la Ortiz-García de la Foz; Obdulia Martínez-García; Rafael Tabarés-Seisdedos; Benedicto Crespo-Facorro; Rosa Ayesa-Arriola
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-10-28       Impact factor: 5.270

6.  The meaning of pharmacological treatment for schizophrenic patients.

Authors:  Kelly Graziani Giacchero Vedana; Adriana Inocenti Miasso
Journal:  Rev Lat Am Enfermagem       Date:  2014 Jul-Aug

7.  Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.

Authors:  Mehmet Fatih Ceylan; Betül Erdogan; Selma Tural Hesapcioglu; Esra Cop
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

8.  Impact of oral antipsychotic medication adherence on healthcare resource utilization among schizophrenia patients with Medicare coverage.

Authors:  Steve Offord; Jay Lin; Bruce Wong; Dario Mirski; Ross A Baker
Journal:  Community Ment Health J       Date:  2013-08-10

9.  Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).

Authors:  Enrico Smeraldi; Roberto Cavallaro; Vera Folnegović-Šmalc; Leszek Bidzan; Mehmet Emin Ceylan; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

10.  Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.

Authors:  Anil K Malhotra; Christoph U Correll; Nabilah I Chowdhury; Daniel J Müller; Peter K Gregersen; Annette T Lee; Arun K Tiwari; John M Kane; W Wolfgang Fleischhacker; Rene S Kahn; Roel A Ophoff; Herbert Y Meltzer; Todd Lencz; James L Kennedy
Journal:  Arch Gen Psychiatry       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.